Ticker brief
IVVD
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
16
authors 14d
4
crowd 14d
+0.9σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-28 · now +0.65 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Pharmdca | C | +0.82 | 8 | +0.54 |
| @semodough | C | -3.01 | 6 | +0.35 |
| @Analytica_X | B | +1.03 | 1 | +0.30 |
| @BiopharmIQ | B | · | 1 | +0.15 |
Recent signals16of 16 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Pharmdca | +0.65 | Frames upcoming biotech readouts as catalysts and calls IVVD a compelling high-risk lotto position. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.40 | Cantor sets a $10 target and views emerging COVID hotspots as positive ahead of IVVD's study readout. | · | tweet ↗ |
| 2026-08-24 | @semodough | +0.00 | Warns the DECLARATION trial's statistical power depends on COVID event incidence. | · | tweet ↗ |
| 2026-08-22 | @BiopharmIQ | +0.15 | Q2 13F data quantify how many of 36 biopharma hedge funds held each named stock. | · | tweet ↗ |
| 2026-08-21 | @semodough | +0.35 | Relays a view that a COVID-tracker spike may portend positive data by quarter-end. | · | tweet ↗ |
| 2026-08-21 | @Pharmdca | +0.75 | Plans to hold an IVVD lottery position through Phase 3 data, citing defined downside and large upside potential. | · | tweet ↗ |
| 2026-08-20 | @semodough | +0.55 | Cites Cantor's $10 target and adds confidence ahead of DECLARATION Phase 3 topline data. | · | tweet ↗ |
| 2026-08-19 | @Pharmdca | +0.80 | Forecasts IVVD near $10 next month on positive data amid strength in vaccine makers such as MRNA. | · | tweet ↗ |
| 2026-08-19 | @semodough | +0.40 | Cantor analyst Schimmer publishes a new IVVD note with a $10 price target. | · | tweet ↗ |
| 2026-08-19 | @Pharmdca | +0.15 | Notes the stock near $1 and an imminent Phase 3 result this quarter. | · | tweet ↗ |
| 2026-08-19 | @Pharmdca | +0.88 | Discloses a speculative IVVD position and a bullish Phase 3 catalyst thesis with a $5-$10+ outcome range. | · | tweet ↗ |
| 2026-08-19 | @Pharmdca | +0.15 | Reports successful Phase 3 melanoma endpoints for Moderna and Merck, plus biotech sympathy moves and an IVVD catalyst. | · | tweet ↗ |
| 2026-08-19 | @Analytica_X | +0.30 | Lists major small-cap gainers and the stated drivers of their moves. | · | tweet ↗ |
| 2026-08-18 | @Pharmdca | +0.55 | Recaps an earlier IVVD binary-event idea and explains its cash-backed risk-reward. | · | tweet ↗ |
| 2026-08-18 | @Pharmdca | +0.40 | H.C. Wainwright set a $10 IVVD target amid multiple clinical-program updates. | · | tweet ↗ |
| 2026-08-18 | @semodough | +0.40 | H.C. Wainwright sets a $10 target while highlighting imminent and late-Q3 clinical readouts. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.